Venus Remedies Bags Marketing Nod from Azerbaijan For Anticoagulant

Venus Remedies Limited, a prominent producer of fixed-dosage injectables, has accomplished a noteworthy milestone by receiving the first marketing authorization for enoxaparin from Azerbaijan. Enoxaparin is an anticoagulant that is essential in preventing blood clot formation in patients with heart attacks, pulmonary embolism, acute coronary syndrome, and deep vein thrombosis.

This achievement is part of the company’s strategy to tap Azerbaijan’s pharmaceutical market, which has an annual volume of $850 million, and thereby expand into West Asia and neighbouring East European countries. Azerbaijan’s pharmaceutical market is import dominated, with India accounting for 4-5 percent of the total pharmaceutical imports, ranking sixth among the top exporting countries, as per pharmabiz Out of the $3 billion worldwide enoxaparin market, around Rs. 500 crore are accounted for by Indian exports. Venus Remedies is a prominent Indian exporter of enoxaparin, with an annual production capacity of over five million units at their robotic line. Enoxaparin, a member of the class of medications known as low molecular weight heparin, inhibits the growth of blood clots that already exist, aids in the body's natural processes for breaking down clots, and stops new blood clots from forming.

Saransh Chaudhary, CEO, Venus Medicine Research Centre, commented on this significant achievement, saying, "We are proud to announce the successful marketing authorisation for enoxaparin in Azerbaijan. This regulatory approval highlights our product's bioequivalence to the innovator compound and underscores our commitment towards facilitating global access to essential medications. Enoxaparin has proven to be a crucial drug in managing various medical conditions related to blood clotting, and we are pleased to make it available to patients in Azerbaijan for the first time."